The advent of boceprevir and telaprevir has led to higher rates o

The advent of boceprevir and telaprevir has led to higher rates of success in the monoinfected

population, and small clinical trials have reported similar success rates in the coinfected population with both boceprevir and telaprevir. In a study of individuals with HCV/HIV infection selleck chemical where telaprevir was administered in combination with PEG-IFN and RBV and compared with PEG-IFN/RBV alone, SVR rates at 24 weeks were 74% and 45%, respectively [71]. A similar study in coinfection has been performed with boceprevir in which SVR rates at 24 weeks were reported as 29% for PEG-IFN/RBV and 63% for PEG-IFN, RBV and boceprevir [72]. No completed study has been performed in HCV/HIV-infected cirrhotics or in individuals who have previously failed interferon and ribavirin therapy, although small series of case reports have been presented. Also, preliminary data from two ANRS studies AZD6244 datasheet in individuals

previously failing therapy with PEG-IFN and RBV have been reported and show virological response rates at week 16 of 88% with telaprevir, including 86% of null responders, and 63% with boceprevir, but only 38% in previous null responders [75–76], although longer-term data are needed before the utility of these drugs in this setting

becomes clear. In monoinfected patients, a recent meta-analysis has suggested a higher response rate when pegylated α-interferon 2a is employed when compared to pegylated α-interferon 2b, although studies involving patients with HIV infection were excluded and therefore no recommendation can be given as to which interferon should be chosen. Nevertheless, based on the monoinfection analysis, physicians may prefer to utilize pegylated α-interferon 2a [89]. Ribavirin should always Carnitine dehydrogenase be given based on weight (1000 mg per day if less than 75 kg and 1200 mg per day if above this weight) [90]. Both telaprevir and boceprevir have drawbacks which include toxicities, drug–drug interactions with antiretrovirals and other commonly used agents, two-or-three-times-daily dosing, and both must be administered with PEG-IFN and RBV. Potential drug–drug interactions of DAAs with both anti-HIV agents and other prescribed medications are of particular importance (see Table 8.1). All individuals should be stabilized on an ART regimen without potential harmful interactions prior to commencement of anti-HCV therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>